Attorney Advertising
Are you a Zenas BioPharma, Inc. (NASDAQ: ZBIO) investor who bought shares in the company’s September 2024 IPO? If so, you may be eligible to join a class action lawsuit now pending in the U.S. District Court for Massachusetts.
The lawsuit alleges that the IPO Registration Statement included materially false and misleading statements and omitted critical information. In particular, it is alleged to have overstated the duration for which Zenas could fund operations with IPO proceeds and existing cash. Read more about the case.
To learn about your legal options, please complete the form below. You may also contact partner Molly J. Bowen at (202) 408-4600 or mbowen@cohenmilstein.com.
CASE BACKGROUND: Zenas BioPharma is a clinical-stage biopharmaceutical company developing immunology-based therapies. A complaint filed on April 16, 2025, in the U.S. District Court for the District of Massachusetts alleges that the company, certain executives and directors, and the underwriters of its IPO violated federal securities laws. The complaint alleges that the Registration Statement for the IPO contained materially false and misleading statements and omitted critical information, particularly overstating the duration Zenas could fund operations with IPO proceeds and existing cash.
Shortly after the IPO, Zenas BioPharma revealed in its third quarter 2024 financial results that it could fund operations for 12 months—not 24 months as previously stated. Following this disclosure, Zenas shares fell significantly, closing at $8.72 per share on April 15, 2025, nearly 49% below the IPO price of $17.00 per share.
NEXT STEPS: If you purchased shares of Zenas BioPharma pursuant and/or traceable to the September 2024 IPO and suffered a significant loss, and are interested in serving as lead plaintiff, you must move the court no later than June 16, 2025, to request appointment as lead plaintiff. You are not required to file a lead plaintiff motion to participate in any potential recovery as a class member.
OUR FIRM: With more than 100 attorneys in eight offices, Cohen Milstein is one of the largest plaintiff-side law firms in the U.S., with over four decades of experience litigating securities fraud cases. We have recovered billions of dollars for investors and are consistently recognized by The National Law Journal, Law360, Chambers USA, and The Legal 500 as a top securities litigation practice. For more information, visit www.cohenmilstein.com.
Prior results do not guarantee a similar outcome. This may be considered Attorney Advertising.
CONTACT INFORMATION:
Molly Bowen, Esq.
Cohen Milstein Sellers & Toll PLLC
Washington, D.C. Office
Email: mbowen@cohenmilstein.com
Website: www.cohenmilstein.com
Are you a participant in the Fitzgerald Auto Mall Employee Stock Ownership Plan (ESOP)?1 If so, you may be owed compensation for financial losses to the ESOP.
On January 31, 2023, the ESOP purchased the company for approximately $440 million. Following the sale, the value of the company’s stock dropped by almost 97% from the stock price the ESOP paid, per Department of Labor filings. As of January 2024, the stock price was still less than 11% of the price the ESOP paid.
If you worked for Fitzgerald Auto Mall for at least one year after January 31, 2022, you may have a claim for losses. Please complete our contact form if you’re interested in learning more. You may also email paralegal Doron Hadar or reach us by phone at 202-408-4671.
If you have already retained a lawyer for this matter, please disregard this communication. Any endorsement in this advertisement does not constitute a guarantee, warranty, or prediction regarding the outcome of your legal matter. Prior results do not guarantee a similar outcome. Attorney Daniel Sutter (admitted only in DC and MD) of the law firm Cohen Milstein Sellers & Toll PLLC, in Washington, DC is investigating this matter. Cohen Milstein’s principal office is located at 1100 New York Avenue NW, Suite 800, Washington, DC 20005, phone number 202-408-4600.
1 The official name of the ESOP is the JJF Management Services Inc. ESOP.
Are you a participant in the BNBuilders, Inc. Employee Stock Ownership Plan (ESOP)? If so, you may be owed compensation for financial losses to the ESOP.
The former owners of BNBuilders sold the company to the ESOP for over $200 million in December 2021. Following the sale, the value of the company’s stock dropped by nearly 90 percent, per Department of Labor filings. It has remained low since, recovering to only about a third of the purchase price by the end of 2023.
If you worked for BNBuilders for at least two years after January 1, 2021, you may have a claim for losses. Please complete our contact form if you’re interested in learning more. You may also email paralegal Doron Hadar or reach us by phone at 202-408-4671.
If you have already retained a lawyer for this matter, please disregard this communication. Any endorsement in this advertisement does not constitute a guarantee, warranty, or prediction regarding the outcome of your legal matter. Prior results do not guarantee a similar outcome. Attorneys Daniel Sutter (admitted only in DC and MD) and Ryan Wheeler (admitted only in CA and DC) of the law firm Cohen Milstein Sellers & Toll PLLC, in Washington, DC are investigating this matter. Cohen Milstein’s principal office is located at 1100 New York Avenue NW, Suite 800, Washington, DC 20005, phone number 202-408-4600.
Cohen Milstein Sellers & Toll LLP is investigating claims on behalf of investors in Profound Medical Corp. (“Profound”) (NASDAQ: PROF). To learn about your legal options, please complete the form on this page or contact Partner Molly Bowen at mbowen@cohenmilstein.com.
CASE BACKGROUND
Profound is a commercial-stage medical device company that develops and markets therapies for the ablation of diseased tissue. On March 6, 2025, Profound announced that the Audit Committee in discussion with Profound’s auditors identified an error which overstated revenue by $472,000 in the first quarter of 2024. Profound determined that the financial statements issued for the first three quarters of 2024 should no longer be relied upon and would be restated and reissued. On this news, Profound’s stock price fell 5.9%, to close at $6.86 per share on March 7, 2025.
NEXT STEPS
If you suffered a significant loss on your investment in PROF and are interested in learning more, you are invited to click here to hear from a member of the Cohen Milstein team or contact Partner Molly Bowen at mbowen@cohenmilstein.com.
OUR FIRM
With more than 100 attorneys in eight offices, Cohen Milstein is one of the largest plaintiff-side law firms in the U.S., with more than four decades of experience litigating securities fraud cases. We have recovered billions of dollars for investors, including $1 billion last year as co-lead counsel in In re Wells Fargo & Company Securities Litigation, and are perennially recognized as one of the best securities practice groups in the country by legal publications such as The National Law Journal, Law360, Chambers USA, and The Legal 500. For more information, visit www.cohenmilstein.com.
Prior results do not guarantee a similar outcome. This may be considered Attorney Advertising.
CONTACT INFORMATION
Molly Bowen, Esq.
Cohen Milstein Sellers & Toll PLLC
Washington, D.C. Office
Email: mbowen@cohenmilstein.com
Website: www.cohenmilstein.com
Investors who lost money on securities of Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI) purchased between August 7, 2024, and February 24, 2025 (the “Class Period”), can contact Cohen Milstein Sellers & Toll PLLC to learn about a new class action securities lawsuit.
To learn about your legal options, complete the form on this page or contact Partner Molly Bowen at mbowen@cohenmilstein.com.
CASE BACKGROUND: Maravai is a life sciences company that provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. A complaint filed in the U.S. District Court for the Southern District of California alleges that the Company and certain current and former officers made false and misleading statements to investors regarding internal controls over financial reporting, revenue recognition, and goodwill valuation in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
Specifically, the lawsuit alleges that throughout the Class Period, Defendants failed to disclose that:
- Maravai lacked adequate internal controls over financial reporting related to revenue recognition;
- As a result, the Company inaccurately recognized revenue on certain transactions during fiscal 2024;
- The Company’s goodwill was overstated; and
- Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
On February 25, 2025, Maravai announced that it was postponing its earnings release and delaying the filing of its annual report due to issues related to revenue recognition and a potential non-cash impairment charge. This news caused the Company’s stock price to decline by approximately 21.7%, resulting in significant losses for investors.
NEXT STEPS: If you suffered a significant loss in MRVI shares purchased during the proposed class period and are interested in serving as lead plaintiff in this action, you have until May 5, 2025, to request that the court appoint you as lead plaintiff. You are not required to file a lead plaintiff motion to share in any recovery in this action as a class member.
OUR FIRM: With more than 100 attorneys in eight offices, Cohen Milstein is one of the largest plaintiff-side law firms in the U.S., with more than four decades of experience litigating securities fraud cases. We have recovered billions of dollars for investors, including $1 billion last year as co-lead counsel in In re Wells Fargo & Company Securities Litigation, and are perennially recognized as one of the best securities practice groups in the country by legal publications such as The National Law Journal, Law360, Chambers USA, and The Legal 500. For more information, visit www.cohenmilstein.com.
Prior results do not guarantee a similar outcome. This may be considered Attorney Advertising.
CONTACT INFORMATION:
Molly Bowen, Esq.
Cohen Milstein Sellers & Toll PLLC
Washington, D.C. Office
Email: mbowen@cohenmilstein.com
Website: www.cohenmilstein.com
View Press Release: Cohen Milstein Urges Shareholders Who Lost Significant Money in Revance Therapeutiucs, Inc. to Contact Firm
Please complete this form relating to your transactions for Revance Therapeutics, Inc. (NASDAQ: RVNC) between February 9, 2024 and December 6, 2024, both dates inclusive.
You may also contact partner Molly Bowen (admitted in DC, FL, and OH) at 202-408-4600 or you may submit your information via email at mbowen@cohenmilstein.com.
View Press Release: Cohen Milstein Urges Shareholders Who Lost Significant Money in Five9, Inc. to Contact Firm
Please complete this form relating to your transactions for Five9, Inc. (NASDAQ: FIVN) between June 4, 2024 and August 8, 2024, both dates inclusive.
You may also contact partner Molly Bowen (admitted in DC, FL, and OH) at 202-408-4600 or you may submit your information via email at mbowen@cohenmilstein.com.
The BDO USA ESOP may have suffered a multimillion-dollar loss in retirement savings. If you worked for BDO on or after August 2023, you may have been impacted. Please complete the contact form to learn more.
Background
In 2023, the leadership of BDO USA sold company stock to the employees through an employee stock ownership plan (ESOP). The ESOP paid some $1.28 billion for BDO stock, according to Department of Labor filings. We believe that ESOP trustees may have had a conflict of interest, causing the ESOP to overpay and incur losses for participants.
These issues could potentially form the basis for a class action lawsuit. The lawsuit would aim to obtain compensation for affected BDO USA ESOP participants, as well as discourage ESOP mismanagement.
If you would like to join our investigation or learn more, please submit our contact form.
About Our Firm
Cohen Milstein Sellers & Toll PLLC is recognized as one of the largest and most diversified plaintiff-side litigation firms in the country — with over 100 attorneys in offices in Washington, DC, New York, Philadelphia, Boston, Chicago, Minneapolis, Palm Beach Gardens, and Raleigh.
Our firm has earned an international reputation by winning complex cases that others did not want to handle. We have litigated numerous groundbreaking cases, some resulting in landmark decisions on previously untried issues involving antitrust, securities, consumer rights, civil rights, and other far-reaching matters.
If you have already retained a lawyer for this matter, please disregard this communication. Any endorsement in this advertisement does not constitute a guarantee, warranty, or prediction regarding the outcome of your legal matter. No representation is made that the quality of the legal services to be performed is greater than the quality of legal services performed by other lawyers. Prior results do not guarantee a similar outcome. Attorneys Ryan Wheeler (admitted in CA and DC), Daniel Sutter (admitted in DC and MD), Caroline Bressman (admitted in DC and MN), and Jacob Schutz (admitted in MN) of Washington, DC-headquartered law firm Cohen Milstein Sellers & Toll PLLC are investigating this matter.
Have you purchased frozen potato products such as French fries, tater tots, or hash browns from a grocery store since 2021? If so, you may have been overcharged—and may be legally owed compensation. Please complete our contact form to learn more.
Background
Since 2021, consumers have had to pay more and more for frozen potato products—even though they’ve gotten cheaper for companies to produce. Why?
Just four companies—Lamb Weston Holdings, Cavendish Farms, McCain Foods, and J.W. Simplot—control over 97 percent of the frozen potato market. We believe that these companies may have illegally colluded to raise prices and keep them high.
These issues could potentially provide the basis for an antitrust class action lawsuit. This lawsuit would seek compensation for consumers who overpaid for frozen potato products. If you would like to take part in our investigation or find out more, please complete the contact form.
About Our Firm
Cohen Milstein is one of the largest and most diversified plaintiff-side litigation firms in the country—with over 100 attorneys in offices in Washington, DC, New York, Philadelphia, Boston, Chicago, Minneapolis, Palm Beach Gardens, and Raleigh.
Our firm has repeatedly won complex class action cases. We have litigated numerous groundbreaking matters, some resulting in landmark decisions on previously untried issues involving antitrust, securities, consumer rights, civil rights, and other far-reaching matters.
The choice of a lawyer is an important decision and should not be based solely upon advertisements. If you have already retained a lawyer for this matter, please disregard this communication. Any endorsement in this advertisement does not constitute a guarantee, warranty, or prediction regarding the outcome of your legal matter. Prior results do not guarantee a similar outcome. Attorneys Brent Johnson (admitted in DC, NY, and NJ), Alison Deich (admitted in DC and VA), Zachary Glubiak (admitted in DC and VA), and Alex Bodaken (admitted in NY) of Washington, DC-based law firm Cohen Milstein Sellers & Toll PLLC are investigating this matter.
View Press Release: Cohen Milstein Urges Shareholders Who Lost Significant Money in Paragon 28, Inc. to Contact Firm
Please complete this form relating to your transactions for Paragon 28, Inc. (NYSE: FNA) between May 5, 2023 and September 20, 2024, both dates inclusive.
You may also contact partner Molly Bowen (admitted in DC, FL, and OH) at 202-408-4600 or you may submit your information via email at mbowen@cohenmilstein.com.